Aquestive Therapeutics, Inc. (AQST) Stock Price & Analysis
Aquestive Therapeutics, Inc. (AQST) rose 2.05% to USD 3.99 as of June 10, 2026 at 07:39 UTC, according to Nexqual real-time market data.
AQST last closed at USD 3.91; the session ranged USD 3.87–4.03 on volume of 1,381,214 shares. Market capitalization is $500.55M, with a 52-week range of USD 2.93–7.55 (NGM). Source: Nexqual, June 10, 2026 at 07:39 UTC.
Key Statistics (as of June 10, 2026 at 07:39 UTC)
| Price | USD 3.99 |
|---|---|
| Change | ▲ 2.05% (up) |
| Previous Close | USD 3.91 |
| Open | USD 3.94 |
| Day Range | USD 3.87 – 4.03 |
| 52-Week Range | USD 2.93 – 7.55 |
| Volume | 1,381,214 shares |
| Market Cap | $500.55M |
| Exchange | NGM |
Technical Analysis (AQST)
Nexqual's technical model rates AQST "SELL" based on 1 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 07:39 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 40.65 (neutral) |
| vs SMA50 | Below (USD 4.14) |
| MACD | -0.06 (negative) |
Analyst Ratings (AQST)
Wall Street analysts rate AQST "None" based on 9 analysts, with a mean price target of USD 8.89 (range USD 6–11), per Nexqual as of June 10, 2026 at 07:39 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 8.89 |
| High Target | USD 11 |
| Low Target | USD 6 |
| Buy / Hold / Sell | 9 / 0 / 0 |
Earnings (AQST)
| Next Earnings Date | 2026-08-11 |
|---|---|
| EPS Estimate | USD -0.12 |
| Revenue Estimate | $11.56M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.05 vs est -0.13 ▲ beat |
| 2025-12-31 | USD -0.14 vs est -0.12 ▼ miss |
| 2025-09-30 | USD -0.11 vs est -0.11 ▼ miss |
| 2025-06-30 | USD -0.12 vs est -0.17 ▲ beat |
Source: Nexqual, June 10, 2026 at 07:39 UTC.
Financials & Fundamentals (AQST)
| Total Revenue | $50.27M |
|---|---|
| Revenue Growth (YoY) | +65.70% |
| Gross Margin | +63.45% |
| Operating Margin | -29.10% |
| Profit Margin | -137.08% |
| Current Ratio | 4.1 |
| Total Cash | $110.73M |
| Total Debt | $43.58M |
| Free Cash Flow | $-25.69M |
Source: Nexqual, June 10, 2026 at 07:39 UTC.
Financial Health Score (AQST)
Nexqual rates Aquestive Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 07:39 UTC.
| Growth | Critical — Revenue -23% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Mixed — $111M cash vs $44M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$26M, burning cash |
| Efficiency | Mixed — No data |
Ownership (AQST)
| Insider Ownership | +3.10% |
|---|---|
| Institutional Ownership | +60.58% |
| Shares Outstanding | 125.45M |
| Float | 114.54M |
| Short % of Float | +12.72% |
Source: Nexqual, June 10, 2026 at 07:39 UTC.
Leadership (AQST)
Aquestive Therapeutics, Inc. is led by Daniel Barber (age 49), CEO, President & Director, per Nexqual as of June 10, 2026 at 07:39 UTC.
| CEO, President & Director | Daniel Barber (age 49) |
|---|---|
| Senior VP & CFO | A. Ernest Toth (age 66) |
| Chief Operating Officer | Cassie Jung (age 46) |
| Senior Vice President of Information Technology & Chief People Officer | Peter E. Boyd (age 59) |
| Senior Vice President of Regulatory Affairs | Melina T. Cioffi Pharm.D. (age 42) |
Major Backers & Investors (AQST)
Notable institutional backers of Aquestive Therapeutics, Inc. include Bratton Capital Management, LP, RTW Investments LP, Federated Hermes, Inc., according to Nexqual as of June 10, 2026 at 07:39 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Bratton Capital Management, LP | 7.82% |
| RTW Investments LP | 5.92% |
| Federated Hermes, Inc. | 3.45% |
| Balyasny Asset Management LP | 2.31% |
| Samsara BioCapital, LLC | 1.99% |
| Bank of America Corporation | 1.92% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 8.36% |
| Vanguard Group | 7.41% |
| State Street | 2.55% |
| Geode Capital | 1.92% |
Source: Nexqual, June 10, 2026 at 07:39 UTC.
From Aquestive Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-04)
Key Strengths & Strategy (as disclosed to the SEC)
- Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally.
- The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata.
- In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SVRA | Savara, Inc. | USD 4.93 | ▼ 3.14% |
| ETON | Eton Pharmaceuticals, Inc. | USD 30.53 | ▲ 4.81% |
| XERS | Xeris Biopharma Holdings, Inc. | USD 6.5 | ▲ 5.18% |
| ALDX | Aldeyra Therapeutics, Inc. | USD 1.72 | ▲ 5.52% |
| ARDX | Ardelyx, Inc. | USD 5.6 | ▲ 0.72% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 07:39 UTC. This page is informational and not investment advice.